JP2022527588A5 - - Google Patents

Info

Publication number
JP2022527588A5
JP2022527588A5 JP2021559754A JP2021559754A JP2022527588A5 JP 2022527588 A5 JP2022527588 A5 JP 2022527588A5 JP 2021559754 A JP2021559754 A JP 2021559754A JP 2021559754 A JP2021559754 A JP 2021559754A JP 2022527588 A5 JP2022527588 A5 JP 2022527588A5
Authority
JP
Japan
Application number
JP2021559754A
Other languages
Japanese (ja)
Other versions
JP2022527588A (ja
JPWO2020207991A5 (https=
JP7692838B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/059831 external-priority patent/WO2020207991A1/en
Publication of JP2022527588A publication Critical patent/JP2022527588A/ja
Publication of JP2022527588A5 publication Critical patent/JP2022527588A5/ja
Publication of JPWO2020207991A5 publication Critical patent/JPWO2020207991A5/ja
Application granted granted Critical
Publication of JP7692838B2 publication Critical patent/JP7692838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559754A 2019-04-09 2020-04-07 自己免疫疾患の治療のためのヘキサヒドロ-1H-ピラジノ[1,2-a]ピラジン化合物 Active JP7692838B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/081900 2019-04-09
CN2019081900 2019-04-09
CNPCT/CN2019/121598 2019-11-28
CN2019121598 2019-11-28
CN2020078225 2020-03-06
CNPCT/CN2020/078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (4)

Publication Number Publication Date
JP2022527588A JP2022527588A (ja) 2022-06-02
JP2022527588A5 true JP2022527588A5 (https=) 2023-04-10
JPWO2020207991A5 JPWO2020207991A5 (https=) 2023-04-10
JP7692838B2 JP7692838B2 (ja) 2025-06-16

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559754A Active JP7692838B2 (ja) 2019-04-09 2020-04-07 自己免疫疾患の治療のためのヘキサヒドロ-1H-ピラジノ[1,2-a]ピラジン化合物

Country Status (19)

Country Link
US (1) US20220340597A1 (https=)
EP (1) EP3953356B1 (https=)
JP (1) JP7692838B2 (https=)
KR (1) KR20210149163A (https=)
CN (1) CN113710672B (https=)
AU (1) AU2020272467A1 (https=)
BR (1) BR112021020297A2 (https=)
CA (1) CA3135129A1 (https=)
CL (1) CL2021002621A1 (https=)
CO (1) CO2021013166A2 (https=)
CR (1) CR20210513A (https=)
IL (1) IL286870A (https=)
MA (1) MA55594A (https=)
MX (1) MX2021012223A (https=)
PE (1) PE20212178A1 (https=)
PH (1) PH12021552533A1 (https=)
SG (1) SG11202110401WA (https=)
TW (1) TW202104230A (https=)
WO (1) WO2020207991A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021084022A1 (en) * 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728959B (zh) * 2019-11-12 2024-11-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
US20240317735A1 (en) * 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562201B (zh) * 2011-01-12 2016-10-19 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
RS56747B1 (sr) 2012-09-14 2018-03-30 Hoffmann La Roche Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest
CN105992766A (zh) * 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EP3807271A1 (en) * 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
JP2022501401A (ja) * 2018-09-27 2022-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のためのヘテロシクリル化合物

Similar Documents

Publication Publication Date Title
JP2022527588A5 (https=)
CN305692346S (https=)
CN305820665S (https=)
CN305667634S (https=)
CN305674569S (https=)
CN305537347S (https=)
CN305536432S (https=)
CN305674069S (https=)
CN305534933S (https=)
CN305534760S (https=)
CN305672679S (https=)
CN305670643S (https=)
CN305534698S (https=)
CN305822533S (https=)
CN305534153S (https=)
CN305532297S (https=)
CN305531347S (https=)
CN305769367S (https=)
CN305531051S (https=)
CN305691786S (https=)
CN305530042S (https=)
CN305529635S (https=)
CN305527567S (https=)
CN305527500S (https=)
CN305947181S (https=)